Brokerages Set Oruka Therapeutics, Inc. (NASDAQ:ORKA) Price Target at $39.86

Oruka Therapeutics, Inc. (NASDAQ:ORKA - Get Free Report) has been given a consensus recommendation of "Buy" by the nine research firms that are currently covering the firm, MarketBeat Ratings reports. Seven equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $39.86.

Several analysts have recently issued reports on ORKA shares. HC Wainwright reiterated a "buy" rating and set a $45.00 price target on shares of Oruka Therapeutics in a research note on Friday, February 7th. Wedbush reiterated an "outperform" rating and set a $40.00 price target on shares of Oruka Therapeutics in a report on Friday, March 7th. Finally, Wolfe Research initiated coverage on shares of Oruka Therapeutics in a research note on Tuesday, February 4th. They issued an "outperform" rating and a $20.00 price objective for the company.

Insider Transactions at Oruka Therapeutics

In other news, major shareholder Venrock Healthcare Capital Par acquired 88,794 shares of the firm's stock in a transaction dated Friday, February 14th. The shares were bought at an average price of $11.44 per share, with a total value of $1,015,803.36. Following the acquisition, the insider now owns 4,148,428 shares of the company's stock, valued at $47,458,016.32. This trade represents a 2.19 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In the last 90 days, insiders have purchased 98,339 shares of company stock worth $1,128,456. 22.67% of the stock is currently owned by company insiders.

Remove Ads

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of ORKA. JPMorgan Chase & Co. acquired a new position in shares of Oruka Therapeutics in the 4th quarter valued at $54,000. AlphaCentric Advisors LLC bought a new stake in Oruka Therapeutics in the fourth quarter valued at about $119,000. China Universal Asset Management Co. Ltd. acquired a new position in Oruka Therapeutics in the fourth quarter worth about $144,000. Squarepoint Ops LLC bought a new position in Oruka Therapeutics during the fourth quarter worth about $236,000. Finally, Charles Schwab Investment Management Inc. acquired a new stake in Oruka Therapeutics during the fourth quarter valued at approximately $303,000. 56.44% of the stock is owned by institutional investors.

Oruka Therapeutics Price Performance

Oruka Therapeutics stock traded up $0.20 during trading hours on Friday, hitting $7.37. The company had a trading volume of 398,874 shares, compared to its average volume of 236,760. The firm's fifty day moving average is $10.62 and its 200-day moving average is $17.96. The firm has a market capitalization of $275.94 million, a P/E ratio of -1.18 and a beta of 0.47. Oruka Therapeutics has a fifty-two week low of $5.49 and a fifty-two week high of $31.13.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last issued its earnings results on Thursday, March 6th. The company reported ($0.49) earnings per share for the quarter, topping the consensus estimate of ($0.68) by $0.19. Analysts anticipate that Oruka Therapeutics will post -3.41 earnings per share for the current year.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.